We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CONMED Corporation | NASDAQ:CNMD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 101.41 | 100.00 | 106.01 | 0 | 01:00:00 |
UTICA, NY--(Marketwired - Feb 13, 2014) - In the news release, "CONMED Corporation Fourth Quarter 2013 Financial Results Exceed Company Guidance," issued earlier today by CONMED Corporation (NASDAQ: CNMD), please be advised that the table headings "Twelve months ended December 31" and "Three months ended December 31" should have been switched for tables RECONCILIATION OF INCOME FROM OPERATIONS TO ADJUSTED INCOME FROM OPERATIONS and RECONCILIATION OF REPORTED NET INCOME TO EBITDA & ADJUSTED EBITDA. Complete corrected text follows.
CONMED Corporation Fourth Quarter 2013 Financial Results Exceed Company Guidance
UTICA, NY -- Feb 13, 2014 -- CONMED Corporation (NASDAQ: CNMD)
CONMED Corporation (NASDAQ: CNMD) today announced financial results for the fourth quarter and year ended December 31, 2013.
"We exited 2013 with strong sales and earnings that exceeded the high end of our guidance for both metrics," said Mr. Joseph J. Corasanti, President and CEO. "Fourth quarter 2013 sales of $203.4 million grew 2.1% on a constant currency basis, compared with a strong performance in the fourth quarter of 2012, and were driven by stronger-than-anticipated sales in Europe and capital equipment products sales. We also achieved sales growth for our single-use and capital products and improved our adjusted gross margins, which led to better-than-expected adjusted earnings per share of $0.53 for the fourth quarter."
Fourth Quarter 2013 Financial Highlights:
Year 2013 Financial Highlights
CONMED generated $27.3 million in cash from operating activities in the fourth quarter of 2013. For 2013, the Company generated $80.9 million in cash from operating activities, more than double the net income for the year. The Company repurchased 1,577,800 shares of its common stock for $50.6 million in 2013 at an average price of $32.04 per share.
Outlook
"We are encouraged by the sales growth acceleration we achieved throughout 2013, particularly in our single-use surgical devices, and are optimistic that the positive trends in surgical procedure growth in both the domestic and international markets will support our continued progress," continued Mr. Corasanti. "We have a dynamic financial model and higher-margin single-use products comprise 80% of CONMED's sales with the remaining 20% of sales resulting from surgical devices that fall under the capital expenditure budgets of our hospital customers. Despite the headwinds our capital products faced throughout 2013 due to continued budgetary restraints at hospitals in the United States and public healthcare systems in other countries, we achieved sales growth among these products that exceeded our expectations for the fourth quarter. Looking forward to 2014, we believe that continued modest improvement in the global economy will allow CONMED to achieve annual sales growth and we are reiterating our 2014 sales and adjusted earnings per share guidance. This forecast is based on our expectations for continued sales growth for our single-use products and continued sales improvement for our capital products as the capital equipment replacement cycle normalizes."
For the first quarter of 2014 CONMED expects to achieve:
For the full year 2014 CONMED expects to achieve:
The adjusted estimates for the first quarter and full year 2014 exclude special items, such as manufacturing restructuring costs expected to be incurred due to relocation of manufacturing activities and patent litigation expense.
Special charges
During the fourth quarter of 2013, the Company continued the on-going consolidation of certain administrative functions and manufacturing activities. Also incurred were litigation costs associated with patent litigation. Further, during the fourth quarter of 2013, the Company incurred a non-cash expense from the settlement of certain pension obligations. Expenses associated with these activities, including severance and relocation costs, amounted to $4.7 million, net of tax, in the fourth quarter of 2013. These charges are included in the GAAP earnings per share set forth above and are excluded from the adjusted results. For 2014, the Company presently anticipates incurring additional pre-tax special costs of $4.0 - 5.0 million on projects currently in process.
Use of non-GAAP financial measures
Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income, adjusted operating income and adjusted earnings per share measure the income of the Company excluding credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Management uses and presents adjusted net income, adjusted operating margin and adjusted earnings per share because management believes that in order to properly understand the Company's short and long-term financial trends, the impact of special items should be eliminated from on-going operating activities. These adjustments for special items are derived from facts and circumstances that vary in frequency and impact on the Company's results of operations. Management uses adjusted net income, adjusted operating income and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company's cash flow. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.
Conference call
The Company will webcast its fourth quarter 2013 conference call live over the Internet at 10:00 a.m. Eastern Time on Thursday, February 13, 2014. This webcast can be accessed from CONMED's web site at www.conmed.com. Replays of the call will be made available through February 21, 2014.
CONMED profile
CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company's 3,600 employees distribute its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 16 countries outside the United States and international sales constitute approximately 50% of the Company's total sales.
Forward Looking Information
This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation or litigation; (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company's ability to devise and execute strategies to respond to market conditions.
CONMED CORPORATION | |||||||||||||
CONSOLIDATED STATEMENTS OF INCOME | |||||||||||||
(In thousands except per share amounts) | |||||||||||||
(unaudited) | |||||||||||||
Three months ended December 31, | Twelve months ended December 31, | ||||||||||||
2012 | 2013 | 2012 | 2013 | ||||||||||
Net sales | $ | 201,244 | $ | 203,442 | $ | 767,140 | $ | 762,704 | |||||
Cost of sales | 91,424 | 89,910 | 354,245 | 341,661 | |||||||||
Cost of sales, other - Note A | 2,533 | 2,137 | 7,052 | 8,626 | |||||||||
Gross profit | 107,287 | 111,395 | 405,843 | 412,417 | |||||||||
Selling and administrative | 79,892 | 82,355 | 302,469 | 310,730 | |||||||||
Research and development | 6,850 | 6,438 | 28,214 | 25,831 | |||||||||
Medical device excise tax | - | 1,536 | - | 5,949 | |||||||||
Other expense- Note B | 3,529 | 4,885 | 9,950 | 13,399 | |||||||||
90,271 | 95,214 | 340,633 | 355,909 | ||||||||||
Income from operations | 17,016 | 16,181 | 65,210 | 56,508 | |||||||||
Loss on early extinguishment of debt | - | - | - | 263 | |||||||||
Interest expense | 1,397 | 1,482 | 5,730 | 5,613 | |||||||||
Income before income taxes | 15,619 | 14,699 | 59,480 | 50,632 | |||||||||
Provision for income taxes | 4,722 | 4,472 | 18,999 | 14,693 | |||||||||
Net income | $ | 10,897 | $ | 10,227 | $ | 40,481 | $ | 35,939 | |||||
Per share data: | |||||||||||||
Net income | |||||||||||||
Basic | $ | .38 | $ | .37 | $ | 1.43 | $ | 1.30 | |||||
Diluted | .38 | .36 | 1.41 | 1.28 | |||||||||
Weighted average common shares | |||||||||||||
Basic | 28,408 | 27,644 | 28,301 | 27,722 | |||||||||
Diluted | 28,727 | 28,062 | 28,653 | 28,114 |
Note A - Included in cost of sales, other in the three and twelve months ended December 31, 2012 and 2013 are costs related to the consolidation of our production facilities. Also included in the twelve months ended December 31, 2013 are costs associated with the termination of a product offering. Refer to the Reconciliation of Reported Net Income to Adjusted Net Income for further details.
Note B - Other expense in the three and twelve months ended December 31, 2012 and 2013 includes a number of adjusted charges. Refer to the Reconciliation of Reported Net Income to Adjusted Net Income for further details.
CONMED CORPORATION | ||||||||||
CONSOLIDATED CONDENSED BALANCE SHEETS | ||||||||||
(in thousands) | ||||||||||
(unaudited) | ||||||||||
ASSETS | ||||||||||
December 31, | ||||||||||
2012 | 2013 | |||||||||
Current assets: | ||||||||||
Cash and cash equivalents | $ | 23,720 | $ | 54,443 | ||||||
Accounts receivable, net | 139,124 | 140,426 | ||||||||
Inventories | 156,228 | 143,211 | ||||||||
Income taxes receivable | 2,897 | 3,805 | ||||||||
Deferred income taxes | 11,931 | 13,202 | ||||||||
Prepaid expenses and other current assets | 14,993 | 17,045 | ||||||||
Total current assets | 348,893 | 372,132 | ||||||||
Property, plant and equipment, net | 139,041 | 138,985 | ||||||||
Deferred income taxes | 1,057 | 1,183 | ||||||||
Goodwill | 248,502 | 248,428 | ||||||||
Other intangible assets, net | 334,185 | 319,440 | ||||||||
Other assets | 7,171 | 10,340 | ||||||||
Total assets | $ | 1,078,849 | $ | 1,090,508 | ||||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||
Current liabilities: | ||||||||||
Current portion of long-term debt | $ | 1,050 | $ | 1,140 | ||||||
Other current liabilities | 124,164 | 110,125 | ||||||||
Total current liabilities | 125,214 | 111,265 | ||||||||
Long-term debt | 160,802 | 214,435 | ||||||||
Deferred income taxes | 99,199 | 113,199 | ||||||||
Other long-term liabilities | 86,636 | 45,290 | ||||||||
Total liabilities | 471,851 | 484,189 | ||||||||
Shareholders' equity: | ||||||||||
Capital accounts | 256,672 | 228,002 | ||||||||
Retained earnings | 377,907 | 395,889 | ||||||||
Accumulated other comprehensive loss | (27,581 | ) | (17,572 | ) | ||||||
Total equity | 606,998 | 606,319 | ||||||||
Total liabilities and shareholders' equity | $ | 1,078,849 | $ | 1,090,508 | ||||||
CONMED CORPORATION | |||||||||||
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS | |||||||||||
(in thousands) | |||||||||||
(unaudited) | |||||||||||
Twelve months ended | |||||||||||
December 31, | |||||||||||
2012 | 2013 | ||||||||||
Cash flows from operating activities: | |||||||||||
Net income | $ | 40,481 | $ | 35,939 | |||||||
Adjustments to reconcile net incometo net cash provided by operating activities: | |||||||||||
Depreciation and amortization | 46,616 | 47,867 | |||||||||
Stock-based compensation | 5,653 | 5,593 | |||||||||
Loss on early extinguishment of debt | - | 263 | |||||||||
Deferred income taxes | 12,946 | 7,218 | |||||||||
Increase (decrease) in cash flows from changes in assets and liabilities: | |||||||||||
Accounts receivable | 1,687 | (798 | ) | ||||||||
Inventories | 3,810 | (1,817 | ) | ||||||||
Accounts payable | 259 | 4,223 | |||||||||
Income taxes receivable (payable) | (6,651 | ) | (1,519 | ) | |||||||
Accrued compensation and benefits | 767 | (71 | ) | ||||||||
Other assets | (1,210 | ) | (5,222 | ) | |||||||
Other liabilities | (9,159 | ) | (10,727 | ) | |||||||
Net cash provided by operating activities | 95,199 | 80,949 | |||||||||
Cash flows from investing activities: | |||||||||||
Payments related to business acquisition and distribution agreement, net of cash acquired | (86,253 | ) | - | ||||||||
Proceeds from sale of property | 1,836 | - | |||||||||
Purchases of property, plant, and equipment | (21,532 | ) | (18,445 | ) | |||||||
Net cash used in investing activities | (105,949 | ) | (18,445 | ) | |||||||
Cash flows from financing activities: | |||||||||||
Payments on debt | (54,657 | ) | (1,277 | ) | |||||||
Proceeds of debt | 73,000 | 55,000 | |||||||||
Payments related to distribution agreement | - | (34,000 | ) | ||||||||
Dividends paid on common stock | (12,862 | ) | (16,696 | ) | |||||||
Payments related to issuance of debt | - | (1,725 | ) | ||||||||
Net proceeds from common stock issued under employee plans | 10,165 | 17,264 | |||||||||
Repurchase of common stock | (3,923 | ) | (50,556 | ) | |||||||
Other, net | (370 | ) | 694 | ||||||||
Net cash provided by (used in) financing activities | 11,353 | (31,296 | ) | ||||||||
Effect of exchange rate change on cash and cash equivalents | (2,931 | ) | (485 | ) | |||||||
Net increase (decrease) in cash and cash equivalents | (2,328 | ) | 30,723 | ||||||||
Cash and cash equivalents at beginning of period | 26,048 | 23,720 | |||||||||
Cash and cash equivalents at end of period | $ | 23,720 | $ | 54,443 | |||||||
CONMED CORPORATION | |||||||||
RECONCILIATION OF REPORTED NET INCOME TO ADJUSTED NET INCOME | |||||||||
Three Months Ended December 31, 2012 and 2013 | |||||||||
(In thousands except per share amounts) | |||||||||
(unaudited) | |||||||||
2012 | 2013 | ||||||||
Reported net income | $ | 10,897 | $ | 10,227 | |||||
Facility consolidation costs | 2,533 | 2,137 | |||||||
Total cost of sales | 2,533 | 2,137 | |||||||
Administrative consolidation costs included in other expense | 3,053 | 2,447 | |||||||
Costs associated with purchase of a business | 476 | - | |||||||
Patent dispute costs included in other expense | - | 995 | |||||||
Pension settlement expense | - | 1,443 | |||||||
Total other expense | 3,529 | 4,885 | |||||||
Adjusted expense before income taxes | 6,062 | 7,022 | |||||||
Provision (benefit) for income taxes on adjusted expenses | (2,074 | ) | (2,351 | ) | |||||
Adjusted net income | $ | 14,885 | $ | 14,898 | |||||
Per share data: | |||||||||
Reported net income | |||||||||
Basic | $ | 0.38 | $ | 0.37 | |||||
Diluted | 0.38 | 0.36 | |||||||
Adjusted net income | |||||||||
Basic | $ | 0.52 | $ | 0.54 | |||||
Diluted | 0.52 | 0.53 | |||||||
Management has provided the above reconciliation of net income to adjusted net income as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section "Use of Non-GAAP Financial Measures" above.
CONMED CORPORATION | |||||||||
RECONCILIATION OF REPORTED NET INCOME TO ADJUSTED NET INCOME | |||||||||
Twelve Months Ended December 31, 2012 and 2013 | |||||||||
(In thousands except per share amounts) | |||||||||
(unaudited) | |||||||||
2012 | 2013 | ||||||||
Reported net income | $ | 40,481 | $ | 35,939 | |||||
Costs associated with termination of a product offering | - | 2,137 | |||||||
Facility consolidation costs | 7,052 | 6,489 | |||||||
Total cost of sales | 7,052 | 8,626 | |||||||
Administrative consolidation costs included in other expense | 6,497 | 8,750 | |||||||
Costs associated with purchase of Nordic region distributor | 704 | - | |||||||
Costs associated with purchase of a business | 1,194 | - | |||||||
Legal arbitration and patent dispute costs included in other expense | 1,555 | 3,206 | |||||||
Pension settlement expense | - | 1,443 | |||||||
Total other expense | 9,950 | 13,399 | |||||||
Loss on early extinguishment of debt | - | 263 | |||||||
Adjusted expense before income taxes | 17,002 | 22,288 | |||||||
Provision (benefit) for income taxes on adjusted expenses | (5,829 | ) | (7,473 | ) | |||||
Adjusted net income | $ | 51,654 | $ | 50,754 | |||||
Per share data: | |||||||||
Reported net income | |||||||||
Basic | $ | 1.43 | $ | 1.30 | |||||
Diluted | 1.41 | 1.28 | |||||||
Adjusted net income | |||||||||
Basic | $ | 1.83 | $ | 1.83 | |||||
Diluted | 1.80 | 1.81 | |||||||
Management has provided the above reconciliation of net income to adjusted net income as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section "Use of Non-GAAP Financial Measures" above.
CONMED CORPORATION | |||||||||||||
RECONCILIATION OF INCOME FROM OPERATIONS TO ADJUSTED INCOME FROM OPERATIONS | |||||||||||||
(In thousands) | |||||||||||||
(unaudited) | |||||||||||||
Three months ended December 31, | Twelve months ended December 31, | ||||||||||||
2012 | 2013 | 2012 | 2013 | ||||||||||
Reported income from operations | $ | 17,016 | $ | 16,181 | $ | 65,210 | $ | 56,508 | |||||
Costs associated with termination of a product offering included in cost of sales | - | - | - | 2,137 | |||||||||
Facility consolidation costs included in cost of sales | 2,533 | 2,137 | 7,052 | 6,489 | |||||||||
Administrative consolidation costs included in other expense | 3,053 | 2,447 | 6,497 | 8,750 | |||||||||
Medical device excise tax | - | 1,536 | - | 5,949 | |||||||||
Costs associated with purchase of a business | 476 | - | 1,194 | - | |||||||||
Costs associated with purchaseof Nordic region distributor | - | - | 704 | - | |||||||||
Legal arbitration and patent dispute costs included in other expense | - | 995 | 1,555 | 3,206 | |||||||||
Pension settlement expense | - | 1,443 | - | 1,443 | |||||||||
Adjusted income from operations | $ | 23,078 | $ | 24,739 | $ | 82,212 | $ | 84,482 | |||||
Operating Margin | |||||||||||||
Reported | 8.5% | 8.0% | 8.5% | 7.4% | |||||||||
Adjusted | 11.5% | 12.2% | 10.7% | 11.1% | |||||||||
Management has provided the above reconciliation as an additional measure that investors can use to compare financial results between reporting periods. Management believes this reconciliation provides a useful presentation of financial measures as discussed in the section "Use of Non-GAAP Financial Measures" above.
CONMED CORPORATION | |||||||||||||
RECONCILIATION OF REPORTED NET INCOME TO EBITDA & ADJUSTED EBITDA | |||||||||||||
(in thousands) | |||||||||||||
(unaudited) | |||||||||||||
Three months ended December 31, | Twelve months ended December 31, | ||||||||||||
2012 | 2013 | 2012 | 2013 | ||||||||||
Net income | $ | 10,897 | $ | 10,227 | $ | 40,481 | $ | 35,939 | |||||
Provision for income taxes | 4,722 | 4,472 | 18,999 | 14,693 | |||||||||
Interest expense | 1,397 | 1,482 | 5,730 | 5,613 | |||||||||
Loss on early extinguishment of debt | - | - | - | 263 | |||||||||
Depreciation | 4,617 | 4,952 | 18,635 | 18,653 | |||||||||
Amortization | 7,100 | 7,228 | 27,305 | 28,655 | |||||||||
EBITDA | $ | 28,733 | $ | 28,361 | $ | 111,150 | $ | 103,816 | |||||
Stock-based compensation | 1,538 | 1,491 | 5,653 | 5,593 | |||||||||
Costs associated with termination of a product offering included in cost of sales | |||||||||||||
- | - | - | 2,137 | ||||||||||
Facility consolidationcosts included in cost of sales | 2,533 | 2,137 | 7,052 | 6,489 | |||||||||
Administrative consolidationcosts included in other expense | 3,053 | 2,447 | 6,497 | 8,750 | |||||||||
Costs associated with purchaseof a business | 476 | - | 1,194 | - | |||||||||
Costs associated with purchase of Nordic region distributor | - | - | 704 | - | |||||||||
Legal arbitration and patent dispute costs included in other expense | - | 995 | 1,555 | 3,206 | |||||||||
Pension settlement expense | - | 1,443 | - | 1,443 | |||||||||
Adjusted EBITDA | $ | 36,333 | $ | 36,874 | $ | 133,805 | $ | 131,434 | |||||
EBITDA Margin | |||||||||||||
EBITDA | 14.3% | 13.9% | 14.5% | 13.6% | |||||||||
Adjusted EBITDA | 18.1% | 18.1% | 17.4% | 17.2% | |||||||||
Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section "Use of Non-GAAP Financial Measures" above.
CONMED CORPORATION | ||||||||||||
Fourth Quarter Sales Summary | ||||||||||||
(in millions) | ||||||||||||
Three Months Ended December 31, | ||||||||||||
2012 | 2013 | Growth | Constant Currency Growth | |||||||||
Orthopedic surgery | $ | 107.0 | $ | 107.7 | 0.7 | % | 2.2 | % | ||||
General surgery | 76.3 | 76.8 | 0.7 | % | 1.2 | % | ||||||
Surgical visualization | 17.9 | 18.9 | 5.6 | % | 5.6 | % | ||||||
$ | 201.2 | $ | 203.4 | 1.1 | % | 2.1 | % | |||||
Single-use products | $ | 160.0 | $ | 161.5 | 0.9 | % | 2.0 | % | ||||
Capital products | 41.2 | 41.9 | 1.7 | % | 2.4 | % | ||||||
$ | 201.2 | $ | 203.4 | 1.1 | % | 2.1 | % | |||||
CONMED CORPORATION | ||||||||||||
Twelve Months Sales Summary | ||||||||||||
(in millions) | ||||||||||||
Twelve Months Ended December 31, | ||||||||||||
2012 | 2013 | Growth | Constant Currency Growth | |||||||||
Orthopedic surgery | $ | 413.9 | $ | 410.2 | -0.9 | % | 0.1 | % | ||||
General surgery | 286.6 | 286.7 | 0.0 | % | 0.5 | % | ||||||
Surgical visualization | 66.6 | 65.8 | -1.2 | % | -0.9 | % | ||||||
$ | 767.1 | $ | 762.7 | -0.6 | % | 0.2 | % | |||||
Single-use products | $ | 611.2 | $ | 609.0 | -0.4 | % | 0.4 | % | ||||
Capital products | 155.9 | 153.7 | -1.4 | % | -0.8 | % | ||||||
$ | 767.1 | $ | 762.7 | -0.6 | % | 0.2 | % | |||||
CONTACT: CONMED Corporation Robert Shallish Chief Financial Officer 315-624-3206
1 Year CONMED Chart |
1 Month CONMED Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions